🎙️ #TJTalks #Podcast #CarTCell #Epigenetics #Oncology
omny.fm/shows/tumori...
@tumorijournal.bsky.social
@tumorijournal.bsky.social
@thecancersurvivorsclub.comCAR-T research continues to push into solid tumours. A second patient has now received the highest dose being studied in a Phase 1 trial of an experimental FSHR-targeted CAR-T therapy for recurrent ovarian cancer.
@achronicvoice.com" #Adicet believes it may be able to sidestep [ #SideEffects ] with a diff kind of #treatment. Its therapy “prula-cel” is derived from the #cells of donors, an “allogeneic” approach that’s quicker & less costly to manufacture.": buff.ly/U0s5mT3
via @biopharmadive.com
#lupus #ClinicalTrial #CARTCell
@thecancersurvivorsclub.comEncouraging early CAR T results: a patient with relapsed AL amyloidosis achieved complete remission within weeks of treatment and has needed no further cancer therapy for more than a year.
@thecancersurvivorsclub.comA new cancer immunotherapy has entered its first human trial. DISP-10 aims to tag solid tumour cells so engineered CAR T cells can find and attack them, initially in advanced gastrointestinal cancers.
@jamaoncology.comAmong children with relapsed or refractory #BCellAcuteLymphoblasticLeukemia, bicistronic CD19/CD22 #CARTCell therapy was associated with high rates of minimal residual disease–negative remission and durable event-free survival. ja.ma/4hc7VYK
@jamaoncology.comđź’¬ Editorial: In pediatric #AcuteLymphoblasticLeukemia, bicistronic CD19/CD22 #CARTCell therapy was associated with durable remission despite limited persistence, challenging the view that prolonged CAR T-cell surveillance is always required. ja.ma/464VxDP